Remain invested in Ranbaxy Lab

Excerpts from Your Stocks on CNBC-TV18 Watch the full show » RELATED NEWS Valtrex patent settlement +ve for Ranbaxy stock Ranbaxy settles patent dispute with GSK on Valacyclovir Ranbaxy & GSK to settle Valacyclovir US Patent Litigation Ranbaxy Lab top gainer on the Sensex Ranbaxy settles dispute with GSK ALSO READ See previous views by PN Vijay See what other Experts & Brokerages are saying about GlaxoSmithKline See messages about GlaxoSmithKline GlaxoSmithKline BSE | NSE 10/02/12 Are Mutual Funds betting on GlaxoSmithKline? Other Stocks in this news Pfizer | Ranbaxy Laboratories |

Investment Advisor, PN Vijay is of the view that is of the view that one should just hold Ranbaxy Laboratories .

Vijay told CNBC-TV18, "Ranbaxy has been hitting the news forever for the wrong reasons, locking horns with the GSK s and Pfizer of the world. At least their lawyers must be less busy now. And the big payment also, which is coming in, exclusivity. So this portion of it is very good. Whether it is enough to take the share out of the total rut it has fallen into, we need a bit more of this type of stuff because time and again, we have seen Ranbaxy get some nice news, go up to Rs 400 and then fall back to Rs 350. We are not sure whether the negative feeling about the whole industry will still affect it. Right now one can just hold it."